Chapters

Transcript

Video

Can you discuss the mechanism of action of DPP-1 inhibitors such as brensocatib and what clinical triggers and associated findings would provide rationale for treating patients with confirmed NCFBE with this new class of agents?


Created by

CMEducation Resources iQ&A Bronchiectasis (NCFBE) Pulmonary Medicine Intelligence Zone

Presenter

Prof. Francesco Blasi, MD, FERS

Prof. Francesco Blasi, MD, FERS

Professor of Respiratory Medicine
Department of Pathophysiology and Transplantation, 
Vice Rector for Relations with the National Health Service
University of Milan
Dean of the School of Medicine, University of Milan
Milan, Italy